Annual CAPEX
$926.40 M
-$690.50 M-42.71%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual capital expenditures is currently $926.40 million, with the most recent change of -$690.50 million (-42.71%) on 31 December 2023. During the last 3 years, it has risen by +$311.80 million (+50.73%). REGN annual CAPEX is now -42.71% below its all-time high of $1.62 billion, reached on 31 December 2022.REGN CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$241.90 M
+$31.00 M+14.70%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly capital expenditures is currently $241.90 million, with the most recent change of +$31.00 million (+14.70%) on 30 September 2024. Over the past year, it has increased by +$42.00 million (+21.01%). REGN quarterly CAPEX is now -77.38% below its all-time high of $1.07 billion, reached on 30 September 2022.REGN Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$928.10 M
+$42.00 M+4.74%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM capital expenditures is currently $928.10 million, with the most recent change of +$42.00 million (+4.74%) on 30 September 2024. Over the past year, it has increased by +$63.00 million (+7.28%). REGN TTM CAPEX is now -47.09% below its all-time high of $1.75 billion, reached on 31 March 2023.REGN TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -42.7% | +21.0% | +7.3% |
| 3 y3 years | +50.7% | +81.6% | +66.2% |
| 5 y5 years | +141.8% | +98.8% | +146.8% |
REGN CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -42.7% | +67.9% | -77.4% | +81.6% | -47.1% | +68.2% |
| 5 y | 5 years | -42.7% | +141.8% | -77.4% | +109.8% | -47.1% | +146.8% |
| alltime | all time | -42.7% | >+9999.0% | -77.4% | +584.8% | -47.1% | +2041.6% |
Regeneron Pharmaceuticals CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $241.90 M(+14.7%) | $928.10 M(+4.7%) |
| June 2024 | - | $210.90 M(+30.3%) | $886.10 M(+9.5%) |
| Mar 2024 | - | $161.80 M(-48.4%) | $809.10 M(-12.7%) |
| Dec 2023 | $926.40 M(-42.7%) | $313.50 M(+56.8%) | $926.40 M(+7.1%) |
| Sept 2023 | - | $199.90 M(+49.3%) | $865.10 M(-50.1%) |
| June 2023 | - | $133.90 M(-52.0%) | $1.73 B(-1.1%) |
| Mar 2023 | - | $279.10 M(+10.7%) | $1.75 B(+8.5%) |
| Dec 2022 | $1.62 B(+193.0%) | $252.20 M(-76.4%) | $1.62 B(+6.4%) |
| Sept 2022 | - | $1.07 B(+596.2%) | $1.52 B(+160.4%) |
| June 2022 | - | $153.60 M(+8.3%) | $583.50 M(+0.9%) |
| Mar 2022 | - | $141.80 M(-8.5%) | $578.40 M(+4.8%) |
| Dec 2021 | $551.90 M(-10.2%) | $154.90 M(+16.3%) | $551.90 M(-1.2%) |
| Sept 2021 | - | $133.20 M(-10.3%) | $558.40 M(-3.5%) |
| June 2021 | - | $148.50 M(+28.8%) | $578.40 M(+3.3%) |
| Mar 2021 | - | $115.30 M(-28.6%) | $559.80 M(-8.9%) |
| Dec 2020 | $614.60 M(+43.1%) | $161.40 M(+5.4%) | $614.60 M(+3.8%) |
| Sept 2020 | - | $153.20 M(+17.9%) | $592.20 M(+5.6%) |
| June 2020 | - | $129.90 M(-23.6%) | $560.70 M(+6.7%) |
| Mar 2020 | - | $170.10 M(+22.4%) | $525.40 M(+22.3%) |
| Dec 2019 | $429.60 M(+12.1%) | $139.00 M(+14.2%) | $429.60 M(+14.2%) |
| Sept 2019 | - | $121.70 M(+28.6%) | $376.10 M(+4.3%) |
| June 2019 | - | $94.60 M(+27.3%) | $360.60 M(-4.6%) |
| Mar 2019 | - | $74.30 M(-13.1%) | $378.00 M(-1.3%) |
| Dec 2018 | $383.10 M(+40.5%) | $85.50 M(-19.5%) | $383.10 M(-5.5%) |
| Sept 2018 | - | $106.20 M(-5.2%) | $405.24 M(+13.0%) |
| June 2018 | - | $112.00 M(+41.1%) | $358.69 M(+19.0%) |
| Mar 2018 | - | $79.40 M(-26.2%) | $301.54 M(+10.6%) |
| Dec 2017 | $272.60 M(-46.7%) | $107.64 M(+80.4%) | $272.60 M(-13.6%) |
| Sept 2017 | - | $59.65 M(+8.8%) | $315.38 M(-15.7%) |
| June 2017 | - | $54.85 M(+8.7%) | $374.28 M(-18.3%) |
| Mar 2017 | - | $50.46 M(-66.5%) | $458.27 M(-10.5%) |
| Dec 2016 | $511.90 M(-24.5%) | $150.41 M(+26.9%) | $511.90 M(-5.1%) |
| Sept 2016 | - | $118.56 M(-14.6%) | $539.26 M(-4.9%) |
| June 2016 | - | $138.84 M(+33.4%) | $566.81 M(-15.1%) |
| Mar 2016 | - | $104.09 M(-41.4%) | $667.87 M(-1.5%) |
| Dec 2015 | $677.93 M(+103.6%) | $177.78 M(+21.7%) | $677.93 M(+9.8%) |
| Sept 2015 | - | $146.10 M(-39.1%) | $617.70 M(+12.0%) |
| June 2015 | - | $239.89 M(+110.1%) | $551.37 M(+44.2%) |
| Mar 2015 | - | $114.16 M(-2.9%) | $382.35 M(+14.8%) |
| Dec 2014 | $333.01 M(+113.0%) | $117.54 M(+47.4%) | $333.01 M(+17.1%) |
| Sept 2014 | - | $79.77 M(+12.6%) | $284.44 M(+20.3%) |
| June 2014 | - | $70.87 M(+9.3%) | $236.36 M(+18.2%) |
| Mar 2014 | - | $64.82 M(-6.0%) | $199.94 M(+27.9%) |
| Dec 2013 | $156.32 M(+216.8%) | $68.98 M(+117.7%) | $156.32 M(+52.5%) |
| Sept 2013 | - | $31.69 M(-8.0%) | $102.51 M(+26.5%) |
| June 2013 | - | $34.45 M(+62.5%) | $81.07 M(+36.3%) |
| Mar 2013 | - | $21.20 M(+39.8%) | $59.48 M(+20.6%) |
| Dec 2012 | $49.34 M(-13.8%) | $15.16 M(+48.0%) | $49.34 M(+8.5%) |
| Sept 2012 | - | $10.25 M(-20.4%) | $45.46 M(+3.1%) |
| June 2012 | - | $12.87 M(+16.4%) | $44.11 M(-4.3%) |
| Mar 2012 | - | $11.05 M(-2.1%) | $46.11 M(-19.4%) |
| Dec 2011 | $57.22 M(-42.6%) | $11.29 M(+26.9%) | $57.22 M(-26.8%) |
| Sept 2011 | - | $8.90 M(-40.1%) | $78.19 M(-14.4%) |
| June 2011 | - | $14.86 M(-32.9%) | $91.39 M(-7.8%) |
| Mar 2011 | - | $22.17 M(-31.3%) | $99.11 M(-0.6%) |
| Dec 2010 | $99.69 M(+2.4%) | $32.26 M(+46.0%) | $99.69 M(+11.1%) |
| Sept 2010 | - | $22.10 M(-2.1%) | $89.74 M(-0.3%) |
| June 2010 | - | $22.58 M(-0.7%) | $89.97 M(-8.3%) |
| Mar 2010 | - | $22.74 M(+1.9%) | $98.14 M(+0.8%) |
| Dec 2009 | $97.32 M(+179.2%) | $22.32 M(-0.1%) | $97.32 M(+7.2%) |
| Sept 2009 | - | $22.33 M(-27.4%) | $90.74 M(+16.7%) |
| June 2009 | - | $30.75 M(+40.3%) | $77.74 M(+44.7%) |
| Mar 2009 | - | $21.92 M(+39.2%) | $53.73 M(+54.1%) |
| Dec 2008 | $34.86 M | $15.74 M(+68.7%) | $34.86 M(+16.8%) |
| Sept 2008 | - | $9.33 M(+38.4%) | $29.85 M(+18.4%) |
| June 2008 | - | $6.74 M(+121.3%) | $25.21 M(+24.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $3.05 M(-71.6%) | $20.30 M(+10.0%) |
| Dec 2007 | $18.45 M(+556.2%) | $10.73 M(+128.7%) | $18.45 M(+106.7%) |
| Sept 2007 | - | $4.69 M(+156.8%) | $8.92 M(+84.0%) |
| June 2007 | - | $1.83 M(+52.6%) | $4.85 M(+44.2%) |
| Mar 2007 | - | $1.20 M(-0.9%) | $3.36 M(+19.6%) |
| Dec 2006 | $2.81 M(-43.4%) | $1.21 M(+95.8%) | $2.81 M(+43.9%) |
| Sept 2006 | - | $617.00 K(+81.5%) | $1.95 M(-36.0%) |
| June 2006 | - | $340.00 K(-47.4%) | $3.05 M(-28.2%) |
| Mar 2006 | - | $646.00 K(+84.0%) | $4.25 M(-14.4%) |
| Dec 2005 | $4.96 M(-19.6%) | $351.00 K(-79.5%) | $4.96 M(-16.4%) |
| Sept 2005 | - | $1.72 M(+11.6%) | $5.94 M(-9.1%) |
| June 2005 | - | $1.54 M(+13.2%) | $6.54 M(-0.2%) |
| Mar 2005 | - | $1.36 M(+2.4%) | $6.55 M(+6.1%) |
| Dec 2004 | $6.17 M(-79.2%) | $1.33 M(-42.7%) | $6.17 M(+0.7%) |
| Sept 2004 | - | $2.31 M(+49.5%) | $6.13 M(-14.9%) |
| June 2004 | - | $1.55 M(+57.2%) | $7.20 M(-32.3%) |
| Mar 2004 | - | $985.00 K(-23.3%) | $10.64 M(-64.1%) |
| Dec 2003 | $29.66 M(-13.7%) | $1.28 M(-62.0%) | $29.66 M(-31.9%) |
| Sept 2003 | - | $3.39 M(-32.0%) | $43.54 M(-10.2%) |
| June 2003 | - | $4.98 M(-75.1%) | $48.47 M(-3.8%) |
| Mar 2003 | - | $20.00 M(+31.9%) | $50.37 M(+46.6%) |
| Dec 2002 | $34.37 M(+318.0%) | $15.17 M(+82.4%) | $34.37 M(+57.7%) |
| Sept 2002 | - | $8.32 M(+20.9%) | $21.80 M(+43.0%) |
| June 2002 | - | $6.88 M(+72.0%) | $15.25 M(+44.1%) |
| Mar 2002 | - | $4.00 M(+53.8%) | $10.58 M(+28.7%) |
| Dec 2001 | $8.22 M(+26.6%) | $2.60 M(+47.1%) | $8.22 M(+21.1%) |
| Sept 2001 | - | $1.77 M(-20.2%) | $6.79 M(+12.0%) |
| June 2001 | - | $2.21 M(+34.7%) | $6.06 M(-4.8%) |
| Mar 2001 | - | $1.64 M(+41.0%) | $6.37 M(-2.0%) |
| Dec 2000 | $6.50 M(+13.9%) | $1.17 M(+11.9%) | $6.50 M(+6.0%) |
| Sept 2000 | - | $1.04 M(-58.7%) | $6.13 M(-2.5%) |
| June 2000 | - | $2.52 M(+42.2%) | $6.29 M(-2.8%) |
| Mar 2000 | - | $1.77 M(+121.4%) | $6.47 M(+13.5%) |
| Dec 1999 | $5.70 M(+90.0%) | $800.00 K(-33.3%) | $5.70 M(+3.6%) |
| Sept 1999 | - | $1.20 M(-55.6%) | $5.50 M(-1.8%) |
| June 1999 | - | $2.70 M(+170.0%) | $5.60 M(+80.6%) |
| Mar 1999 | - | $1.00 M(+66.7%) | $3.10 M(+3.3%) |
| Dec 1998 | $3.00 M(+42.9%) | $600.00 K(-53.8%) | $3.00 M(0.0%) |
| Sept 1998 | - | $1.30 M(+550.0%) | $3.00 M(+42.9%) |
| June 1998 | - | $200.00 K(-77.8%) | $2.10 M(+16.7%) |
| Mar 1998 | - | $900.00 K(+50.0%) | $1.80 M(-14.3%) |
| Dec 1997 | $2.10 M(-75.6%) | $600.00 K(+50.0%) | $2.10 M(0.0%) |
| Sept 1997 | - | $400.00 K(-500.0%) | $2.10 M(-4.5%) |
| June 1997 | - | -$100.00 K(-108.3%) | $2.20 M(-56.0%) |
| Mar 1997 | - | $1.20 M(+100.0%) | $5.00 M(-41.9%) |
| Dec 1996 | $8.60 M(+160.6%) | $600.00 K(+20.0%) | $8.60 M(-19.6%) |
| Sept 1996 | - | $500.00 K(-81.5%) | $10.70 M(+0.9%) |
| June 1996 | - | $2.70 M(-43.8%) | $10.60 M(+32.5%) |
| Mar 1996 | - | $4.80 M(+77.8%) | $8.00 M(+142.4%) |
| Dec 1995 | $3.30 M(-52.2%) | $2.70 M(+575.0%) | $3.30 M(+3200.0%) |
| Sept 1995 | - | $400.00 K(+300.0%) | $100.00 K(-75.0%) |
| June 1995 | - | $100.00 K(0.0%) | $400.00 K(-73.3%) |
| Mar 1995 | - | $100.00 K(-120.0%) | $1.50 M(-78.3%) |
| Dec 1994 | $6.90 M(-32.4%) | -$500.00 K(-171.4%) | $6.90 M(-55.5%) |
| Sept 1994 | - | $700.00 K(-41.7%) | $15.50 M(-3.1%) |
| June 1994 | - | $1.20 M(-78.2%) | $16.00 M(+3.2%) |
| Mar 1994 | - | $5.50 M(-32.1%) | $15.50 M(+52.0%) |
| Dec 1993 | $10.20 M(+385.7%) | $8.10 M(+575.0%) | $10.20 M(-121.3%) |
| Sept 1993 | - | $1.20 M(+71.4%) | -$47.80 M(-2755.6%) |
| June 1993 | - | $700.00 K(+250.0%) | $1.80 M(0.0%) |
| Mar 1993 | - | $200.00 K(-100.4%) | $1.80 M(-14.3%) |
| Dec 1992 | $2.10 M(+110.0%) | -$49.90 M(-198.2%) | $2.10 M(-96.0%) |
| Sept 1992 | - | $50.80 M(+7157.1%) | $52.00 M(+4233.3%) |
| June 1992 | - | $700.00 K(+40.0%) | $1.20 M(+140.0%) |
| Mar 1992 | - | $500.00 K | $500.00 K |
| Dec 1991 | $1.00 M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual capital expenditures?
- What is the all time high annual CAPEX for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual CAPEX year-on-year change?
- What is Regeneron Pharmaceuticals quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly CAPEX year-on-year change?
- What is Regeneron Pharmaceuticals TTM capital expenditures?
- What is the all time high TTM CAPEX for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM CAPEX year-on-year change?
What is Regeneron Pharmaceuticals annual capital expenditures?
The current annual CAPEX of REGN is $926.40 M
What is the all time high annual CAPEX for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual capital expenditures is $1.62 B
What is Regeneron Pharmaceuticals annual CAPEX year-on-year change?
Over the past year, REGN annual capital expenditures has changed by -$690.50 M (-42.71%)
What is Regeneron Pharmaceuticals quarterly capital expenditures?
The current quarterly CAPEX of REGN is $241.90 M
What is the all time high quarterly CAPEX for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly capital expenditures is $1.07 B
What is Regeneron Pharmaceuticals quarterly CAPEX year-on-year change?
Over the past year, REGN quarterly capital expenditures has changed by +$42.00 M (+21.01%)
What is Regeneron Pharmaceuticals TTM capital expenditures?
The current TTM CAPEX of REGN is $928.10 M
What is the all time high TTM CAPEX for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM capital expenditures is $1.75 B
What is Regeneron Pharmaceuticals TTM CAPEX year-on-year change?
Over the past year, REGN TTM capital expenditures has changed by +$63.00 M (+7.28%)